

PERSONAL INFORMATION

**Evelina Tacconelli**

📍 P.le L.A. Scuro, 10 – 37134 Verona (work)

📞 +39 0458128243

✉️ evelina.tacconelli@univr.it

Date of Birth: 26/11/1967

Nationality: Italian

PROFESSIONAL EXPERIENCE

Since 10/ 2018	Head of Infectious Diseases Division, University of Verona; ID-CARE (Infectious Diseases Centre for TrAnslation REsearch), University of Verona
Since 10/ 2017	Full Professor, Infectious Diseases, University of Verona, Italy
Since 01/ 2021	Lecturer on Antimicrobial Resistance, DZIF Research Clinical Unit on healthcare associated infections and antimicrobial resistance, Infectious Diseases, Dept. Internal Medicine I, Tübingen University, Germany
2012 - 2020	Head of the DZIF Research Clinical Unit on healthcare associated infections and antimicrobial resistance, Tübingen University, Germany
2012 - 2017	Full Professor, Infectious Diseases, University of Tübingen, Germany
2013 - 2018	Medical Director Comprehensive Center for infectious Diseases, University Hospital Tübingen
2013 - 2017	Head of Infectious Diseases Division, Internal Medicine I, University hospital, Tübingen
2003 - 2007	Lecturer on Medicine, Infectious Diseases, BIDMC and Harvard Medical School, Boston, USA
1999 - 2013	Assistant Professor, Infectious Diseases, Catholic University, Rome, Italy
1997 - 1999	Infectious Diseases Specialist, Catholic University, Rome, Italy

EDUCATION

09/1986 - 07/1992	Medical University (09/1986 –07/1992; 110/110 cum laude), Università Cattolica di Roma, Rome, Italy
09/1992 - 07/1996	Infectious Diseases Specialization (09/1992 –07/1996; 60/60 cum laude), Università Cattolica di Roma, Rome, Italy
09/1997- 06/1998	Master for Public Health Operators, Università la Sapienza, Rome, Italy

SCHOLARSHIPS, AWARDS & PRICES

2020	"Lowbury Lecture for Excellence in Research in Prevention of Healthcare Associated Infections", Hospital Infections Society, UK
2004	"Young Investigator Award for Clinical Microbiology and Infectious Diseases" European Society of Clinical Microbiology and Infectious Diseases
2003	"Young Investigator Award for the Study on Antibiotic Resistance". Slovak Society of Chemotherapy, Slovakia
1998	"Junior Scholarship Award, University of London, for Curricula Studiorum and Abstract Presentation at 4 th International Congress on Drug Therapy in HIV Infection", Glasgow.
1997	National scholarship for studies on AIDS, National Institute of Health, Italy

EDITORIAL BOARDS (selection)

Since 2020	Senior Editor, Journal of Antimicrobial Chemotherapy
Since 2014	Scientific Committee, Clinical Microbiology and Infection
Since 2012	International Advisory Board, Lancet Infectious Diseases
2009 - 2019	Editorial Board, Journal of Antimicrobial Chemotherapy
2004 - 2013	Associated Editor, Clinical Microbiology and Infection

SOCIETY & BOARD (selection)

Since 2021	Coordinator of the national working group on improving antibiotics' prescriptions, Italian Medicine Agency (AIFA)
Since 2021	Veneto Region Working Group, Italy – Infectious Diseases Priority Plan, expert member
Since 2021	Working Group for the coordination of the national plan on antimicrobial resistance (PNCAR, Minister of Health), expert member
Since 2021	ESCMID guidelines for the prevention of surgical site infections, Chairman
Since 2021	ESCMID guidelines for screening policies for healthcare workers to reduce the spread of SARS-CoV-2, Chairman
Since 2021	Working group for the treatment of COVID-19 with monoclonal antibodies, Veneto Region, expert member
Since 2021	Working group for the treatment of COVID-19 with monoclonal antibodies, AIFA, expert member
Since 2020	Consultant for antibiotic therapy, Italian medicine Agency (AIFA)
Since 2020	Working Group for appropriateness of hospital admission of patients with COVID-19 therapy (National Agency for Regional Health Services, AGENAS), expert member
Since 2020	Scientific Committee for prevention and therapy of SARS-CoV-2 infection, Veneto Region, Italy, expert member
Since 2020	WHO Expert Group on Identifying Priority Fungal Pathogens, expert member
Since 2019	Regional Committee for the implementation of antimicrobial stewardship by national plan on antimicrobial resistance recommendations, Veneto Region, Chairman

Since 2019	World Health Organisation (WHO) Essential Medicine List, Antibiotics Working Group, expert member
Since 2019	Selection Committee for the Department of Health and Social Care Antimicrobial Resistance Research Capital Funding Competition, NHS, UK (Capital: £32 million), Coordinator Deputy
Since 2019	Master on Nursing Specialist on epidemiological surveillance and control of health-care associated infections, University of Verona, Italy, Coordinator
Since 2018	Scientific Board of JPI-AMR (Joint Programming Initiative on Antimicrobial Resistance, European Commission), expert member
Since 2018	Regional Therapeutic Committee, expert member, Veneto Region, Italy
Since 2018	Scientific Committee, expert member, IRCCS Sacro Cuore – Don Calabria', Negrar, Italy.
Since 2015	Chair of EUCIC (European Committee of Infection Control)
Since 2010	ESCMID guidelines to control of hospital spreading of multidrug-resistant gram-negative bacteria, Chairman (update 2020)
Since 2009	European Center for Diseases Control (ECDC) Consultant for antibiotic stewardship and Multi Drug-Resistant (MDR) gram negative bacteria
2018 - 2019	WHO Priority List of antimicrobial resistant bacteria for R&D of effective antibiotics, Chairman
2017 - 2019	ESCMID guidelines Officer of Infectious Diseases and Clinical Microbiology
2016 - 2019	ESCMID guidelines for decolonisation of MDR gram-negative bacteria, Chairman
2009 - 2017	ESCMID Education Officer of Infectious Diseases and Clinical Microbiology
2014 - 2017	Clinical Advisory Board, HZI (Helmholtz Zentrum für Infektionsforschung, Germany), expert member
2014 - 2016	Advisory Board, expert member, German Society for Infectious Diseases, DGI (Deutsche Gesellschaft für Infektiologie, Germany)
2009 - 2013	Study Group on Antibiotic Resistance in Hospitalised Patients, Italian Society of Infectious Diseases (SIMIT), Chairman
2012 - 2013	External Affairs Committee, expert member, SHEA (Society of Healthcare Epidemiologists of America)
2012 - 2013	ESCMID Study Group on Infections in the Elderly (ESGIE), Chairman
2008 - 2012	ISC (International Society of Chemotherapy) Working Group on MRSA - Risk assessment, Chairman

RESEARCH PROJECTS (selection of last 10 years)

Date	National and International Studies	Sponsor	Role & Budget (Euro)
From 2021	MANTICO: Adaptive group sequential randomized control trial (Phase III) to assess the efficacy of monoclonal antibodies for the treatment of light to moderate COVID-19 disease.	AIFA	Coordinator 980.000

From 2021	PRIMAVERA: Vaccines And Monoclonal antibodies: Predicting the Impact on Antimicrobial Resistance and an Economic evaluation.	IMI	Partner 280.275
From 2021	AMMURAVID: Factorial, multicentre, randomized clinical trial of Remdesivir and immunotherapy in combination with dexamethasone for moderate COVID-19.	AIFA	Coordinator
From 2021	VACCELERATE-Italy: European Corona Vaccine Trial Accelerator Platform.	Horizon2020	National coordinator 92.361
From 2021	ECRAID BASE: European Clinical Research Alliance on Infectious Diseases	Horizon2020	Partner 999.815
From 2021	REVERSE: Prevention and management tools for reducing antibiotic Resistance in high prevalence Settings.	Horizon2020	National coordinator 2.317.882
From 2020	ORCHESTRA: Connecting European Cohorts to Increase Common and Effective Response to SARS-CoV-2 Pandemic.	Horizon2020	Coordinator 27.779.642
From 2020	WHO Solidarity Trial: international clinical trial to help find an effective treatment for COVID-19.	WHO	In-kind contribution
From 2020	ENACT: Alliance against COVID-19.	Fondazione CariVerona	WP leader 886.234
From 2020	EU-RESPONSE: European Research and Preparedness Network for Pandemics and Emerging Infectious Diseases.	Horizon2020	National coordinator 217.047
From 2020	SARS-CoV-2 Surveillance in school and public places.	CORIS Regione Veneto	Partner 338.000
From 2019	Development of a web tool to perform surveillance connected to antibiotic prescription in hospital and community.	CORIS Regione Veneto	Coordinator 210.000
From 2019	VALUE DX – IMI Study: The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use.	IMI	WP leader 83.705
From 2019	EXPECT-1 and EXPECT-2: Pilot Study to Assess Success Factors And Barriers for Preparation of a Phase 3 Randomized Controlled Study With ExPEC10V in Adults Aged 60-85 Years With History of Urinary Tract Infection in Stable Health.	IMI	Partner 900.000
2019	WHO Tender: Systematic review to develop a WHO Index integrated in the AWARE index to measure optimal antibiotic usage	WHO	Coordinator 21.000

2019	WHO Tender: Duration of antibiotic therapy to treat community acquired pneumonia.	WHO	Coordinator 22.000
From 2019	DZIF-PREDICT Validation of the BLOOMY score for mortality.	DZIF	Coordinator 89.900
2019-2021	COMBACTE-MAGNET (IMI 2015) "Understanding of the epidemiology and clinical impact of Clostridium difficile infection"	IMI	Partner 40.000
2020- 2021	SENTINELLA: Rapid identification of SARS-CoV-2 in vulnerable population	Fondazione della Comunità Veronese	Coordinator 737.640
Since 2019	BIOSTEPS: Personalised surgical prophylaxis in pancreatic surgery in high AMR prevalence	AIFA (Italian Medicine Agency)	Partner 100.000
2018-2021	MODERN: Understanding and modelling reservoirs, vehicles and transmission of ESBL-producing Enterobacteriaceae in the community and long term care facilities.	Horizon 2020	WP leader 680.000
2018-2020	COHERENCE project: Combination therapy to treat sepsis due to carbapenem-Resistant bacteria in adult and paediatric population: Evidence and common practice	GARDP (Global Antibiotic Research and Development Partnership)	Coordinator 120.000
2015-2020	DZIF-R-Net Surveillance for antibiotic resistant infections	DZIF	Partner 95.900
2012-2020	DZIF (German Center for Infectious Diseases Research) Clinical Trial Unit specialised for research on prevention and treatment of HAIs	DZIF	Coordinator 1.101.000
2018-2019	CONNECT Project: "increasing communication, awareness and data sharing in a global approach against resistance"	JPI-AMR	In-kind contribution
2018-2019	GAP-One Project: "Global Antimicrobial resistance Platform for ONE Burden Estimates".	JPI-AMR	In-kind contribution
2018-2019	ARCH Project: Bridging the gap between <u>human</u> and animal surveillance data, antibiotic policy, and stewardship. Design: Consensus-driven guidelines development and research priority setting.	JPI-AMR	Coordinator 50.000
2017-2019	JPIAMR: CASE Project: White paper on design of studies on antibiotic stewardship.	JPIAMR	In-kind contribution

2016-2019	Sonderlinie Medizin „Perspektive 2020“, Baden-Württemberg: „Surveillance of multidrug resistant bacteria in human and animal in Baden Württemberg“.	Baden-Württemberg	Coordinator 340.000
2015-2019	DZIF-ABSOLUTE Antimicrobial stewardship to reduce resistance	DZIF	Partner 99.700
2015-2019	DZIF-BLOOMY Solution for the improvement of bloodstream infections	DZIF	Coordinator 72.600
2017-2018	Burden of antibiotic resistant infection (GLASS initiative)	WHO	Coordinator 35.000
2016-2018	IMI-2016-COMBACTE-MAGNET- ICU-ASPIRE	IMI	Partner 89.000
2014-2018	DRIVE-AB (IMI-2014): “Driving reinvestment in R&D and appropriate usage of antibiotics	IMI (Innovative Medicines Initiative)	Partner 373.600
2016-2017	Priority list for AMR pathogens for the R&D for new antibiotics.	WHO	Coordinator 144.000
2012-2015	DZIF-ATHOS Antimicrobial stewardship in community and healthcare facilities.	DZIF	Partner 63.000
2012-2015	DZIF- SPECTRUM- Risk factors for Clostridium difficile at hospital admission”	DZIF	Partner 60.000
2012-2015	“Excellence in Research in Infectious Diseases”, University of Tübingen.	EKUT	Coordinator 240.000
2012-2014	“Is There a Predominance of Gram-Negative Bacterial Bloodstream Infections in Countries with Warmer Climates?”	Tel-Aviv University	In-kind contribution
2010-2014	SATURN: impact of specific antibiotic therapies on the prevalence of human host resistant bacteria.	FP7	WP leader 848.000
2011-2013	“Producing guidance for prevention and control of methicillin-resistant Staphylococcus aureus (MRSA)” (Publication Reference: OJ/12/12/2008 - PROC/2008/045).	ECDC	In-kind contribution
2011-2013	Preserving old antibiotics for the future: assessment of clinical efficacy by a pharmacokinetic/pharmacodynamic approach to optimize effectiveness and reduce resistance for off patent antibiotics (AIDA).	FP7	Partner 264.640
2010-2013	European Grant DG Sanco Implementing Strategic Bundles for Infection Prevention & Management	DG Sanco	Partner 87.156

PUBLICATIONS (2018-2021)

1. Gentilotti, E., De Nardo, P., Cremonini, E., Górska, A., Mazzaferri, F., Canziani, L.M., Hellou, M.M., Olchowski, Y., Poran, I., Leeflang, M. and Villacian, J., 2021. Diagnostic accuracy of point-of-care tests in acute community acquired-lower respiratory tract infections. A systematic review and meta-analysis. *Clinical Microbiology and Infection*.
2. Maaike S.M. van Mourik, Stephanie M. van Rooden, Mohamed Abbas, Olov Aspevall, Pascal Astagneau, Marc J.M. Bonten, Elena Carrara, Aina Gomila-Grange, Sabine C. de Greeff, Sophie Gubbels, Wendy Harrison, Hilary Humphreys, Anders Johansson, Mayke B.G. Koek, Brian Kristensen, Alain Lepape, Jean-Christophe Lucet, Siddharth Mookerjee, Pontus Naucler, Zaira R. Palacios-Baena, Elisabeth Presterl, Miquel Pujol, Jacqui Reilly, Christopher Roberts, Evelina Tacconelli, Daniel Teixeira, Thomas Tängdén, John Karlsson Valik, Michael Behnke, Petra Gastmeier, PRAISE: providing a roadmap for automated infections surveillance in Europe, *Clinical Microbiology and Infection*, Volume 27, Supplement 1, 2021, Pages S3-S19, ISSN 1198-743X.
3. Righi, E., Mirandola, M., Mazzaferri, F., Razzaboni, E., Zaffagnini, A., Erbogasto, A., ... & Tacconelli, E. (2021). Long-Term Patient-Centred Follow-up in a Prospective Cohort of Patients with COVID-19. *Infectious Diseases and Therapy*, 1-12.
4. van Rooden, S. M., Aspevall, O., Carrara, E., Gubbels, S., Johansson, A., Lucet, J.-C., Mookerjee, S., Palacios-Baena, Z. R., Presterl, E., Tacconelli, E., Abbas, M., Behnke, M., Gastmeier, P., & van Mourik, M. S. M. (2021). Governance aspects of large-scale implementation of automated surveillance of healthcare-associated infections. *Clinical Microbiology and Infection*, 27, S20–S28.
5. Olaru, I. D., Tacconelli, E., Yeung, S., Ferrand, R. A., Stabler, R. A., Hopkins, H., Aiken, A. M., & Kranzer, K. (2021). The association between antimicrobial resistance and HIV infection: a systematic review and meta-analysis. *Clinical Microbiology and Infection*, 27(6), 846–853. <https://doi.org/10.1016/J.CMI.2021.03.026>
6. Tacconelli E, Linking infection control to clinical management of infections to overcome antimicrobial resistance, *Journal of Hospital Infection*, May 2021, ISSN 0195-6701.
7. Scudeller L, Righi E, Chiamenti M, Bragantini D, Menchinelli G, Cattaneo P, Giske C, Lodise T, Sanguinetti M, J.V. Piddock L, Franceschi F, Ellis S, Carrara E, Savoldi A, Tacconelli E, Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli, *International Journal of Antimicrobial Agents*, Volume 57, Issue 5, 2021, 106344, ISSN 0924-8579.
8. Savoldi A, Carrara E, Piddock LJ, Franceschi F, Ellis S, Chiamenti M, Bragantini D, Righi E, Tacconelli E. The role of combination therapy in the treatment of severe infections caused by carbapenem resistant gram-negatives: a systematic review of clinical studies. *BMC infectious diseases*. 2021 Dec; 21(1):1-1.
9. Gentilotti E, Savoldi A, Compri M, Górska A, De Nardo P, Visentin A, Be G, Razzaboni E, Soriolo N, Meneghin D, Girelli D. Identifying COVID-19 Progression by Day Five From Symptoms Onset.
10. Rodríguez-Baño J, Rossolini GM, Schultsz C, Tacconelli E, et al. Key considerations on the potential impacts of the COVID-19 pandemic on antimicrobial resistance research and surveillance. *Trans R Soc Trop Med Hyg*. 2021 Mar 27.
11. Righi E, Gallo T, Azzini AM, Mazzaferri F, Cordioli M, Merighi M, Tacconelli E. A Review of Vaccinations in Adult Patients with Secondary Immunodeficiency. *Infect Dis Ther*. 2021 Mar 9:1–25.
12. Adami G, Giollo A, Fassio A, Benini C, Bertoldo E, Bertoldo F, Orsolini G, Idolazzi L, Viapiana O, Giannini S, Passeri G, Tacconelli E, et al. Vitamin D and disease severity in coronavirus disease 19 (COVID-19). *Reumatismo*. 2021 Jan 18;72(4):189-196.
13. Bost P, De Sanctis F, Canè S, Ugel S, Donadello K, Castellucci M, Eyal D, Fiore A, Anselmi C, Barouni RM, Trovato R, Caligola S, Lamolinara A, Iezzi M, Facciotti F, Mazzariol A, Gibellini D, De Nardo P, Tacconelli E, et al. Deciphering the state of immune silence in fatal COVID-19 patients. *Nat Commun*. 2021 Mar 5;12(1):1428.
14. Rodríguez-Baño J, Rossolini GM, Schultsz C, Tacconelli E, et al. Antimicrobial resistance research in a post-pandemic world: Insights on antimicrobial resistance research in the COVID-19 pandemic. *J Glob Antimicrob Resist*. 2021 Mar 1; 25:5-7.
15. WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernández García C, Kieny MP, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, BarrattDue A, Bellani S, Branca M, Cappel-Porter HBC, Cerrato N, Chow TS, Como N, Eustace J, García PJ, Godbole S, Gotuzzo E, Grishevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portolés A, Rasmin MR, Raza A, Rees H, Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. *N Engl J Med*. 2021 Feb

16. Theuretzbacher U, Carrara E, Conti M, Tacconelli E. Role of new antibiotics for KPC-producing Klebsiella pneumoniae. *J Antimicrob Chemother.* 2021 Jan 29; 76(Supplement_1):i47-i54.
17. Pezzani MD, Tornimbene B, Pessoa-Silva C, de Kraker M, Rizzato S, Salerno ND, Harbarth S, Tacconelli E. Methodological quality of studies evaluating the burden of drug-resistant infections in humans due to the WHO Global Antimicrobial Resistance Surveillance System target bacteria. *Clin Microbiol Infect.* 2021 Jan 13:S1198- 743X (21)00006-9.
18. Riccio ME, Verschuren T, Conzelmann N, Martak D, Meunier A, Salamanca E, Delgado M, Guther J, Peter S, Paganini J, Martischang R, Sauser J, de Kraker MEA, Cherkaoui A, Fluit AC, Cooper BS, Hocquet D, Kluytmans JA JW, Tacconelli E, et al.; MODERN WP2 study group. Household acquisition and transmission of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae after hospital discharge of ESBL-positive index patients. *Clin Microbiol Infect.* 2021 Jan 7:S1198-743X (20)30784-9.
19. Pezzani MD, Mazzaferri F, Compri M, Galia L, Mutters NT, Kahlmeter G, Zaoutis TE, Schwaber MJ, Rodríguez-Baño J, Harbarth S, Tacconelli E; COACH working group. Linking antimicrobial resistance surveillance to antibiotic policy in healthcare settings: the COMBACTE-Magnet EPI-Net COACH project. *J Antimicrob Chemother.* 2020 Dec 6; 75 (Suppl 2):ii2-ii19.
20. Compri M, Mader R, Mazzolini E, de Angelis G, Mutters NT, Babu Rajendran N, Galia L, Tacconelli E, Schrijver R; ARCH working group. White Paper: Bridging the gap between surveillance data and antimicrobial stewardship in the animal sector-practical guidance from the JPIAMR ARCH and COMBACTE-MAGNET EPI-Net networks. *J Antimicrob Chemother.* 2020 Dec 6; 75(Suppl 2).
21. Sibani M, Mazzaferri F, Carrara E, Pezzani MD, Arieti F, Göpel S, Paul M, Tacconelli E, Mutters NT, Voss A; ARCH working group. White Paper: Bridging the gap between surveillance data and antimicrobial stewardship in long-term care facilities-practical guidance from the JPIAMR ARCH and COMBACTE-MAGNET EPI-Net networks. *J Antimicrob Chemother.* 2020 Dec 6; 75.
22. Pezzani MD, Carrara E, Sibani M, Presterl E, Gastmeier P, Renk H, Kanj SS, Velavan TP, Song LH, Leibovici L, Torumkuney D, Kostyanev T, Mendelson M, Tacconelli E; ARCH working group. White Paper: Bridging the gap between human and animal surveillance data, antibiotic policy and stewardship in the hospital sector-practical guidance from the JPIAMR ARCH and COMBACTE-MAGNET EPI-Net networks. *J Antimicrob Chemother.* 2020 Dec 6; 75(Suppl 2):ii20-ii32.
23. Arieti F, Göpel S, Sibani M, Carrara E, Pezzani MD, Murri R, Mutters NT, López-Cerero L, Voss A, Cauda R, Tacconelli E; ARCH working group. White Paper: Bridging the gap between surveillance data and antimicrobial stewardship in the outpatient sector-practical guidance from the JPIAMR ARCH and COMBACTE-MAGNET EPI-Net networks. *J Antimicrob Chemother.* 2020 Dec 6; 75 (Suppl 2):ii42-ii51. doi:10.1093/jac/dkaa428. PMID: 33280045; PMCID: PMC7719405.
24. Morel CM, Alm RA, Årdal C, Bandera A, Bruno GM, Carrara E, Colombo GL, de Kraker MEA, Essack S, Frost I, Gonzalez-Zorn B, Goossens H, Guardabassi L, Harbarth S, Jørgensen PS, Kanj SS, Kostyanev T, Laxminarayan R, Leonard F, Hara GL, Mendelson M, Mikulska M, Mutters NT, Outterson K, Baño JR, Tacconelli E, Scudeller L; GAPONE network. A one health framework to estimate the cost of antimicrobial resistance. *Antimicrob Resist Infect Control.* 2020 Nov.
25. Mustafa Hellou M, Górska A, Mazzaferri F, Cremonini E, Gentilotti E, De Nardo P, Poran I, Leeflang MM, Tacconelli E, Paul M. Nucleic acid amplification tests on respiratory samples for the diagnosis of coronavirus infections: a systematic review and meta-analysis. *Clin Microbiol Infect.* 2021 Mar;27(3):341-351. doi: 10.1016/j.cmi.2020.11.002.
26. Tsiotis C, Birgand G, Bathoorn E, Deptula A, Ten Horn L, Castro-Sánchez E, Săndulescu O, Widmer AF, Tsakris A, Piev G, Tacconelli E, Mutters NT. Education and training programmes for infection prevention and control professionals: mapping the current opportunities and local needs in European countries. *Antimicrob Resist Infect Control.* 2020 Nov 9; 9(1):183.
27. Piacentini D, Lanzafame M, Rizzato S, Chiesi S, Lattuada E, Mehrabi S, Zamboni G, Mazzi R, Tacconelli E, Vento S. Increase in visceral adipose tissue in a woman living with HIV after introduction of integrase strand transfer inhibitor. *Int J STD AIDS.* 2020 Dec; 31(14):1407-1410.
28. Pizzolo F, Rigoni AM, De Marchi S, Friso S, Tinazzi E, Sartori G, Stefanoni F, Nalin F, Montagnana M, Pilotto S, Milella M, Azzini AM, Tacconelli E, Marchi G, Girelli D, Olivieri O, Martinelli N. Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg. *Thromb Res.* 2020 Oct; 194:216-219.
29. Taus F, Salvagno G, Canè S, Fava C, Mazzaferri F, Carrara E, Petrova V, Barouni RM, Dima F, Dalbeni A, Romano S, Poli G, Benati M, De Nitto S, Mansueti G, Iezzi M, Tacconelli E, et al. Platelets Promote Thromboinflammation in SARS-CoV-2 Pneumonia. *Arterioscler Thromb Vasc Biol.* 2020 Dec;40(12):2975-2989.
30. Vehreschild MJGT, Tacconelli E, Giske CG, Peschel A. Beyond COVID-19-a paradigm shift in infection management? *Lancet Infect Dis.* 2020 Oct 9:S1473-3099(20)30789-1.
31. Marchi G, Vianello A, Crisafulli E, Maroccia A, Crinò SF, Pecori S, Zamboni GA, Mazzaferri F, Tacconelli E,

- Girelli D. Cytomegalovirus-Induced Gastrointestinal Bleeding and Pancreatitis Complicating Severe Covid-19 Pneumonia: A Paradigmatic Case. *Mediterr J Hematol Infect Dis.* 2020 Sep; 32. Ambrosetti MC, Battocchio G, Zamboni GA, Fava C, Tacconelli E, Mansueti G. Rapid onset of bronchiectasis in COVID19 Pneumonia: two cases studied with CT. *Radiol Case Rep.* 2020 Nov;15(11):2098-2103. 33. Bielicki JA, Duval X, Gobat N, Goossens H, Koopmans M, Tacconelli E, van der Werf S. Monitoring approaches for health-care workers during the COVID-19 pandemic. *Lancet Infect Dis.* 2020 Oct; 20(10):e261-e267. 34. Xanthopoulou K, Peter S, Tobys D, Behnke M, Dinkelacker AG, Eisenbeis S, Falgenhauer J, Falgenhauer L, Fritzenwanker M, Götz H, Häcker G, Higgins PG, Imlazlioglu C, Käding N, Kern WV, Kramme E, Kola A, Mischnik A, Rieg S, Rohde AM, Rupp J, Tacconelli E, et al.; DZIF R-Net Study Group. Vancomycin-resistant Enterococcus faecium colonizing patients on hospital admission in Germany: prevalence and molecular epidemiology. *J Antimicrob Chemother.* 2020 Oct 1; 75(10):2743-2751. 35. Deelen JWT, Rottier WC, Giron Ortega JA, Rodriguez-Baño J, Harbarth S, Tacconelli E, Jacobsson G, Zahar JR, van Werkhoven CH, Bonten MJM; ESBL-PREDICT Study Team. An international prospective cohort study to validate two prediction rules for infections caused by 3rd-generation cephalosporin-resistant Enterobacterales. *Clin Infect Dis.* 2020 Jul 8:ciaa950. 36. De Nardo P, Gentilotti E, Mazzaferri F, Cremonini E, Hansen P, Goossens H, Tacconelli E; members of the COVID19MCDA Group. Multi-Criteria Decision Analysis to prioritize hospital admission of patients affected by COVID-19 in low-resource settings with hospital-bed shortage. *Int J Infect Dis.* 2020 37. Solbach P, Chhatwal P, Woltemate S, Tacconelli E, Buhl M, Autenrieth IB, Vehreschild MJGT, Jazmati N, Gerhard M, Stein-Thoeringer CK, Rupp J, Ulm K, Ott A, Lasch F, Koch A, Manns MP, Suerbaum S, Bachmann O. Microbiotaassociated risk factors for *C. difficile* acquisition in hospitalized patients: A prospective, multicentric study. *Clin Infect Dis.* 2020 Jun 26:ciaa871. 38. Zuliani S, Zampiva I, Tregnago D, Casali M, Cavaliere A, Fumagalli A, Merler S, Riva ST, Rossi A, Zacchi F, Zaninotto E, Auriemma A, Pavarana M, Soldà C, Benini L, Borghesani M, Caldart A, Casalino S, Gaule M, Kadrija D, Mongillo M, Pesoni C, Biondani P, Cingarlini S, Fiorio E, Melisi D, Parolin V, Tondulli L, Belluomini L, Zecchetto C, Avesani B, Biasi A, Bovo C, Dazzani E, Dodi A, Gelmini S, Leta LC, Lo Cascio G, Lombardo F, Lucin E, Martinelli IA, Messineo L, Moscarda V, Pafumi S, Reni A, Sartori G, Scaglione IM, Shoval Y, Sposito M, Tacconelli E, Trestini I, Zambonin V, Zanelli S, Pilotto S, Milella M. Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic. *Eur J Cancer.* 2020 Aug; 135:159-169. 39. Mariotto S, Savoldi A, Donadello K, Zanzoni S, Bozzetti S, Carta S, Zivelonghi C, Alberti D, Piraino F, Minuz P, Girelli D, Crisafulli E, Romano S, Marcon D, Marchi G, Gottin L, Polati E, Zanatta P, Monaco S, Tacconelli E, Ferrari S. Nervous system: subclinical target of SARS-CoV-2 infection. *J Neurol Neurosurg Psychiatry.* 2020 Sep;91(9):1010-1012. 40. Azzini AM, Dorizzi RM, Sette P, Vecchi M, Coledan I, Righi E, Tacconelli E. A 2020 review on the role of procalcitonin in different clinical settings: an update conducted with the tools of the Evidence Based Laboratory Medicine. *Ann Transl Med.* 2020 May; 8(9):610. 41. Minuz P, Mansueti G, Mazzaferri F, Fava C, Dalbeni A, Ambrosetti MC, Sibani M, Tacconelli E. High rate of pulmonary thromboembolism in patients with SARS-CoV-2 pneumonia. *Clin Microbiol Infect.* 2020 Nov; 26(11):1572-1573. 42. Mehrabi S, Fontana S, Mambrin F, Nguyen HQ, Righi E, Tacconelli E, Mansueti G. Pitfalls of Computed Tomography in the Coronavirus 2019 (COVID-19) Era: A New Perspective on Ground-Glass Opacities. *Cureus.* 2020 May 16;12(5):e8151 43. Savoldi A, Carrara E, Tacconelli E. Gross national income and antibiotic resistance in invasive isolates: analysis of the top-ranked antibiotic-resistant bacteria on the 2017 WHO priority list-authors' response. *J Antimicrob Chemother.* 2020 Jul 1; 75(7):2018. doi: 10.1093/jac/dkaa203. PMID: 32459829. 44. Savoldi A, Foschi F, Kreth F, Gladstone BP, Carrara E, Eisenbeis S, Buhl M, Marasca G, Bovo C, Malek NP, Tacconelli E. Impact of implementing a non-restrictive antibiotic stewardship program in an emergency department: a four-year quasi-experimental prospective study. *Sci Rep.* 2020 May 18; 10(1):8194. 45. Niehus R, van Kleef E, Mo Y, Turlej-Rogacka A, Lammens C, Carmeli Y, Goossens H, Tacconelli E, Carevic B, Preotescu L, Malhotra-Kumar S, Cooper BS. Quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase resistance. *Elife.* 2020 May 7; 9:e49206. 46. Anaya-Baz B, Maldonado N, Palacios-Baena ZR, Palomo V, Pezzani MD, Chiesi S, Razzaboni E, Compri M, Tacconelli E, Rodriguez-Baño J. Systematic literature review of the burden and outcomes of infections due to multidrug-resistant organisms in Europe: the ABOUT-MDRO project protocol. *BMJ Open.* 2020 May; 10(5):e030608. 47. Rohde AM, Zweigner J, Wiese-Posselt M, Schwab F, Behnke M, Kola A, Schröder W, Peter S, Tacconelli E et al. Prevalence of third-generation cephalosporin-resistant Enterobacterales colonization on hospital admission and ESBL genotype-specific risk factors: a cross-sectional study in six German university

- hospitals. *J Antimicrob Chemother.* 2020 Jun 1;75(6):1631-1638
48. Theuretzbacher U, Bush K, Harbarth S, Paul M, Rex JH, Tacconelli E, Thwaites GE. Critical analysis of antibacterial agents in clinical development. *Nat Rev Microbiol.* 2020 May; 18(5):286-298.
49. Lo Cascio G, Vincenzi M, Soldani F, De Carolis E, Maccacaro L, Sorrentino A, Nadali G, Cesaro S, Sommavilla M, Niero V, Naso L, Grancini A, Azzini AM, Sanguinetti M, Tacconelli E, Cornaglia G. Outbreak of *Saprochaete clavata* Sepsis in Hematology Patients: Combined Use of MALDI-TOF and Sequencing Strategy to Identify and Correlate the Episodes. *Front Microbiol.* 2020 Jan 31; 11:84.
50. Birgand G, Mutters NT, Ahmad R, Tacconelli E, Lucet JC, Holmes A; Percept-R Study Group. Risk perception of the antimicrobial resistance by infection control specialists in Europe: a case-vignette study. *Antimicrob Resist Infect Control.* 2020 Feb 14; 9(1):33.
51. Shamsrizi P, Gladstone BP, Carrara E, Luise D, Cona A, Bovo C, Tacconelli E. Variation of effect estimates in the analysis of mortality and length of hospital stay in patients with infections caused by bacteria-producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. *BMJ Open.* 2020
52. Goletti D, Navarra A, Petruccioli E, Cimaglia C, Compagno M, Cuzzi G, De Carli G, Fondaco L, Franzetti F, Giannetti A, Gori A, Lapadula G, Lichtner M, Mastrianni CM, Mazzotta V, Orchi N, Pavone P, Piacentini D, Pirriatore V, Pontali E, Sarmati L, Spolti A, Tacconelli E, et al. Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: A multicentre study promoted by the Italian Society of Infectious and Tropical Diseases. *Int J Infect Dis.* 2020 Mar; 92:62-68.
53. Van Rooden SM, Tacconelli E, Pujol M, Gomila A, Kluytmans JA JW, Romme J, Moen G, Couvé-Deacon E, Bataille C, Rodríguez Baño J, Lanz J, van Mourik MSM. A framework to develop semiautomated surveillance of surgical site infections: An international multicenter study. *Infect Control Hosp Epidemiol.* 2020
54. Babu Rajendran N, Mutters NT, Marasca G, Conti M, Sifakis F, Vuong C, Voss A, Baño JR, Tacconelli E; COMBACTEMAGNET-EPI-Net Consortium. Mandatory surveillance and outbreaks reporting of the WHO priority pathogens for research & discovery of new antibiotics in European countries. *Clin Microbiol Infect.* 2020 Jul; 26(7):943.e1-943.
55. Sharland M, Gandra S, Huttner B, Moja L, Pulcini C, Zeng M, Mendelson M, Cappello B, Cooke G, Magrini N; EML Expert Committee and Antibiotic Working Group. Encouraging AWaRe-ness and discouraging inappropriate antibiotic use-the new 2019 Essential Medicines List becomes a global antibiotic stewardship tool. *Lancet Infect Dis.* 2019 Dec; 19(12):1278-1280.
56. Babich T, Naucler P, Valik JK, Giske CG, Benito N, Cardona R, Rivera A, Pulcini C, Fattah MA, Haquin J, MacGowan A, Grier S, Chazan B, Yanovskay A, Ami RB, Landes M, Nesher L, Zaidman-Shimshovitz A, McCarthy K, Paterson DL, Tacconelli E, et al. Risk factors for mortality among patients with *Pseudomonas aeruginosa* bacteraemia: a retrospective multicentre study. *Int J Antimicrob Agents.* 2020 Feb; 55(2):105847.
57. Savoldi A, Carrara E, Gladstone BP, Azzini AM, Göpel S, Tacconelli E. Gross national income and antibiotic resistance in invasive isolates: analysis of the top-ranked antibiotic-resistant bacteria on the 2017 WHO priority list. *J Antimicrob Chemother.* 2019 Dec 1; 74(12):3619-3625.
58. Schweitzer VA, van Werkhoven CH, Rodríguez Baño J, Bielicki J, Harbarth S, Hulscher M, Huttner B, Islam J, Little P, Pulcini C, Savoldi A, Tacconelli E et al; Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) Working Group on Design of Antimicrobial Stewardship Evaluations. Optimizing design of research to evaluate antibiotic stewardship interventions: consensus recommendations of a multinational working group. *Clin Microbiol Infect.* 2020 Jan; 26(1):41-50.
59. Chiesi S, Rizzato S, Piacentini D, Be G, Lattuada E, Tacconelli E, Lanzafame M. Low plasmatic concentration of intensified antiretroviral therapy in a pregnant woman: a case report. *J Med Case Rep.* 2019 Jul 23; 13(1):224.
60. Babich T, Naucler P, Valik JK, Giske CG, Benito N, Cardona R, Rivera A, Pulcini C, Abdel Fattah M, Haquin J, MacGowan A, Grier S, Gibbs J, Chazan B, Yanovskay A, Ben Ami R, Landes M, Nesher L, Zaidman-Shimshovitz A, McCarthy K, Paterson DL, Tacconelli E, et al. Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for *Pseudomonas aeruginosa* Bloodstream Infection: A Multisite Retrospective Study. *Clin Infect Dis.* 2020 May 23; 70(11):2270-2280.
61. Rizzato S, Lanzafame M, Lattuada E, Luise D, Vincenzi M, Tacconelli E, Vento S. Dolutegravir monotherapy and body weight gain in antiretroviral naïve patients. *AIDS.* 2019 Aug 1; 33(10):1673-1674.
62. Donisi V, Sibani M, Carrara E, Del Piccolo L, Rimondini M, Mazzaferri F, Bovo C, Tacconelli E. Emotional, cognitive and social factors of antimicrobial prescribing: can antimicrobial stewardship intervention be effective without addressing psycho-social factors? *J Antimicrob Chemother.* 2019 Oct 1; 74(10):2844-2847.
63. Zingg W, Storr J, Park BJ, Jernigan JA, Harbarth S, Grayson ML, Tacconelli E, Alleganzi B, Cardo D, Pittet D; 2017 Geneva-IPC Think Tank. Broadening the infection prevention and control network globally; 2017 Geneva IPC-think tank (part 3). *Antimicrob Resist Infect Control.* 2019 May 10;8:74
64. Saris K, Meis JF, Baño JR, Tacconelli E, van de Belt TH, Voss A. Does Online Search Behavior Coincide with *Candida auris* Cases? An Exploratory Study. *J Fungi (Basel).* 2019 Jun 4;5(2):44
65. Zingg W, Storr J, Park BJ, Ahmad R, Tarrant C, Castro-Sánchez E, Tomczyk S, Kilpatrick C, Alleganzi B,

- Cardo D, Pittet D; 2017 Geneva IPC-Think Tank. Implementation research for the prevention of antimicrobial resistance and healthcare-associated infections; 2017 Geneva infection prevention and control (IPC)-think tank (part 1). *Antimicrob Resist Infect Control.* 2019 May 28; 8:87.
66. Zingg W, Park BJ, Storr J, Ahmad R, Tarrant C, Castro-Sanchez E, Perencevich E, Widmer A, Krause KH, Kilpatrick C, Tomczyk S, Allegranzi B, Cardo D, Pittet D; 2017 Geneva IPC-Think Tank. Technology for the prevention of antimicrobial resistance and healthcare-associated infections; 2017 Geneva IPC-Think Tank (Part 2). *Antimicrob Resist Infect Control.* 2019 May 22; 8:83.
67. Tacconelli E, Górska A, De Angelis G, Lammens C, Restuccia G, Schrenzel J, Huson DH, Carević B, Preoteșcu L, Carmeli Y, Kazma M, Spanu T, Carrara E, Malhotra-Kumar S, Gladstone BP. Estimating the association between antibiotic exposure and colonization with extended-spectrum β-lactamase-producing Gram-negative bacteria using machine learning methods: a multicentre, prospective cohort study. *Clin Microbiol Infect.* 2020 Jan; 26(1):87-94.
68. Tacconelli E, Buhl M, Humphreys H, Malek V, Presterl E, Rodriguez-Baño J, Vos MC, Zingg W, Mutters NT; EUCIC StopNegative group. Analysis of the challenges in implementing guidelines to prevent the spread of multidrugresistant gram-negatives in Europe. *BMJ Open.* 2019 May 19; 9(5):e027683.
69. Nicolè S, Lanzafame M, Lattuada E, Luise D, Vecchi M, Tacconelli E, Vento S. Efavirenz dose reduction is associated with improved lipid profile in HIV-1 infected patients. *Infect Dis (Lond).* 2019 Aug; 51(8):615-617.
70. Rizzato S, Lanzafame M, Lattuada E, Bragantini D, Nicolè S, Calza L, Tacconelli E. Efficacy and safety of abacavir/lamivudine with raltegravir in treatment-experienced and treatment-naïve patients with HIV-1 infection: an observational, retrospective, multi-centre study. *Int J STD AIDS.* 2019 Apr; 30(5):467-471.
71. Tacconelli E, Cataldo MA, Mutters NT, Carrara E, Bartoloni A, Raglio A, Cauda R, Mantengoli E, Luzzaro F, Pan A, Beccara LA, Pecile P, Tinelli M, Rossolini GM. Role of place of acquisition and inappropriate empirical antibiotic therapy on the outcome of extended-spectrum β-lactamase-producing Enterobacteriaceae infections. *Int J Antimicrob Agents.* 2019 Jul; 54(1):49-54.
72. Tacconelli E, Mazzaferri F, de Smet AM, Bragantini D, Eggimann P, Huttner BD, Kuijper EJ, Lucet JC, Mutters NT, Sanguinetti M, Schwaber MJ, Souli M, Torre-Cisneros J, Price JR, Rodríguez-Baño J. ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram-negative bacteria carriers. *Clin Microbiol Infect.* 2019 Jul; 25(7):807-817. doi: 10.1016/j.cmi.2019.01.005.
73. Rohde AM, Zweigner J, Wiese-Posselt M, Schwab F, Behnke M, Kola A, Obermann B, Knobloch JK, Feihl S, Querbach C, Gebhardt F, Mischnik A, Ihle V, Schröder W, Armean S, Peter S, Tacconelli E, et al.; DZIF-ATHOS study group. Incidence of infections due to third generation cephalosporin-resistant Enterobacteriaceae - a prospective multicentre cohort study in six German university hospitals. *Antimicrob Resist Infect Control.* 2018 Dec 27; 7:159.
74. Meletiadis J, Turlej-Rogacka A, Lerner A, Adler A, Tacconelli E, Mouton JW. Erratum for Meletiadis et al., "Amplification of Antimicrobial Resistance in Gut Flora of Patients Treated with Ceftriaxone". *Antimicrob Agents Chemother.* 2018 Nov 26; 62(12):e02184-18.
75. Schweitzer VA, van Heijl I, van Werkhoven CH, Islam J, Hendriks-Spoor KD, Bielicki J, Bonten MJM, Walker AS, Llewelyn MJ; Consensus on Antimicrobial Stewardship Evaluations (CASE) study group. The quality of studies evaluating antimicrobial stewardship interventions: a systematic review. *Clin Microbiol Infect.* 2019 May; 25(5):555- 561.
76. Dyar OJ, Beović B, Pulcini C, Tacconelli E, Hulscher M, Cookson B; ESCMID generic competencies working group. ESCMID generic competencies in antimicrobial prescribing and stewardship: towards a European consensus. *Clin Microbiol Infect.* 2019 Jan; 25(1):13-19.
77. Tacconelli E, Pezzani MD. Public health burden of antimicrobial resistance in Europe. *Lancet Infect Dis.* 2019 Jan; 19(1):4-6.
78. Carrara E, Bragantini D, Tacconelli E. Combination versus monotherapy for the treatment of infections due to carbapenem-resistant Enterobacteriaceae. *Curr Opin Infect Dis.* 2018 Dec; 31(6):594-599.
79. Scudeller L, Rodríguez-Baño J, Zinkernagel A, Tacconelli E, Akova M, Friedrich AW, Sanguinetti M, Paul M, Poljak M. ESCMID white paper: a guide on ESCMID guidance documents. *Clin Microbiol Infect.* 2019 Feb; 25(2):155-162.
80. Temkin E, Fallach N, Almagor J, Gladstone BP, Tacconelli E, Carmeli Y; DRIVE-AB Consortium. Estimating the number of infections caused by antibiotic-resistant Escherichia coli and Klebsiella pneumoniae in 2014: a modelling study. *Lancet Glob Health.* 2018 Sep;6(9):e969-e979.
81. De Backer S, Xavier BB, Vanjari L, Coppens J, Lammens C, Vemu L, Carevic B, Hryniwicz W, Jorens P, Kumar-Singh S, Lee A, Harbarth S, Schrenzel J, Tacconelli E, Goossens H, Malhotra-Kumar S. Remarkable geographical variations between India and Europe in carriage of the staphylococcal surface protein-encoding sasX/seS1 and in the population structure of methicillin-resistant Staphylococcus aureus belonging to clonal complex 8. *Clin Microbiol Infect.* 2019
82. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. *Gastroenterology.*

- 2018 Nov;155(5):1372-1382.e17
83. Russo A, Falcone M, Gutiérrez-Gutiérrez B, Calbo E, Almirante B, Viale PL, Oliver A, Ruiz-Garbajosa P, Gasch O, Gozalo M, Pitout J, Akova M, Peña C, Cisneros JM, Hernández-Torres A, Farcomeni A, Prim N, Origüen J, Bou G, Tacconelli E, et al.; REIPI/ESGBIS/INCREMENT investigators. Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β -lactamase-producing Enterobacteriaceae. *Int J Antimicrob Agents.* 2018 Nov; 52(5):577-585.
84. Van de Belt TH, van Stockum PT, Engelen LJPG, Lancee J, Schrijver R, Rodríguez-Baño J, Tacconelli E, Saris K, van Gelder MMHJ, Voss A. Social media posts and online search behaviour as early-warning system for MRSA outbreaks. *Antimicrob Resist Infect Control.* 2018 May 30; 7:69.
85. Solbach P, Chhatwal P, Woltemate S, Tacconelli E, Buhl M, Gerhard M, Thoeringer CK, Vehreschild MJGT, Jazmati N, Rupp J, Manns MP, Bachmann O, Suerbaum S. BaiCD gene cluster abundance is negatively correlated with Clostridium difficile infection. *PLoS One.* 2018 May 8; 13(5):e0196977.
86. Scheuerman O, Schechner V, Carmeli Y, Gutiérrez-Gutiérrez B, Calbo E, Almirante B, Viale PL, Oliver A, Ruiz-Garbajosa P, Gasch O, Gozalo M, Pitout J, Akova M, Peña C, Molina J, Hernández-Torres A, Venditti M, Prim N, Origüen J, Bou G, Tacconelli E, et al.; REIPI/ESGBIS/INCREMENT investigators. Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing Escherichia coli and ESBL-Producing Klebsiella pneumoniae. *Infect Control Hosp Epidemiol.* 2018 Jun; 39(6):660-667.
87. Rohde AM, Wiese-Posselt M, Zweigner J, Schwab F, Mischnik A, Seifert H, Gastmeier P, Kern WV; DZIF-ATHOS Study Group. High admission prevalence of fluoroquinolone resistance in third-generation cephalosporin-resistant Enterobacteriaceae in German university hospitals. *J Antimicrob Chemother.* 2018 Jun 1;73(6):1688-1691
88. Savoldi A, Azzini AM, Baur D, Tacconelli E. Is there still a role for vancomycin in skin and soft-tissue infections? *Curr Opin Infect Dis.* 2018 Apr;31(2):120-130
89. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavalieri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N; WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect Dis.* 2018 Mar; 18(3):318-327.
90. Magiorakos AP, Burns K, Rodríguez Baño J, Borg M, Daikos G, Dumpis U, Lucet JC, Moro ML, Tacconelli E, Simonsen GS, Szilágyi E, Voss A, Weber JT. Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings: guidance from the European Centre for Disease Prevention and Control. *Antimicrob Resist Infect Control.* 2017 Nov 15;6:113
91. Tacconelli E, Sifakis F, Harbarth S, Schrijver R, van Mourik M, Voss A, Sharland M, Rajendran NB, Rodríguez-Baño J; EPI-Net COMBACTE-MAGNET Group. Surveillance for control of antimicrobial resistance. *Lancet Infect Dis.* 2018 Mar; 18(3):e99-e106.
92. Mutters NT, Malek V, Agnandji ST, Günther F, Tacconelli E. Evaluation of the scientific impact of the Ebola epidemic: a systematic review. *Clin Microbiol Infect.* 2018 Jun;24(6):573-576

Verona, 03/11/2021



Evelina Tacconelli